Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: NEUP

Neuphoria Therapeutics Inc.

Healthcare | Medical - Pharmaceuticals

No licensed closing price on file for NEUP. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (FY2026)$-3.06

Neuphoria Therapeutics Inc. (NASDAQ: NEUP) is a pharmaceutical company. Figures from SEC EDGAR; updated 2026-10-20 09:58 UTC.

What Neuphoria Therapeutics Inc. does

Neuphoria is a clinical-stage biotechnology company developing therapies for neuropsychiatric disorders, with its lead candidate BNC210, an oral drug designed to treat social anxiety disorder and post-traumatic stress disorder by modulating the alpha-7 nicotinic acetylcholine receptor. BNC210 is advancing through Phase 3 trials for social anxiety disorder, with patient screening underway for the AFFIRM-1 trial, while a Phase 2b trial in PTSD met its primary endpoint.

Summarized from Neuphoria Therapeutics Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (FY2026)$-3.06

Revenue, margins & earnings

FY2025: net loss $369,632 on revenue $16M$16MFY2025FY2026: net loss $13M on revenue $1M$1MFY2026
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity
Source: SEC EDGAR · Filed 2026-01-21
Most recent filed transactions — January 2026:
  • 2026-01-21DirectorRestricted Stock UnitsAward8,537—
  • 2026-01-21DirectorRestricted Stock UnitsAward17,073—
  • 2026-01-21DirectorRestricted Stock UnitsAward8,537—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Neuphoria Therapeutics Inc. do?

Neuphoria is a clinical-stage biotechnology company developing therapies for neuropsychiatric disorders, with its lead candidate BNC210, an oral drug designed to treat social anxiety disorder and post-traumatic stress disorder by modulating the alpha-7 nicotinic acetylcholine receptor.

When did NEUP last file with the SEC?

Neuphoria Therapeutics Inc.'s most recent SEC filing on record is a 8-K filed 2026-05-26. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 09:58 UTC. This page is also available as JSON at /api/data?ticker=NEUP and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for NEUP and 5,000+ tickers.

Create a free account — keep NEUP
For your agent
GET /api/data?ticker=NEUP

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt